<div><div></div><div><span><p><strong><span>Moleculin announced an ASCO poster acceptance presenting pooled cardiac safety data for Annamycin showing no evidence of drug-induced cardiotoxicity.</span></strong></p><p><strong><span>Key Highlights:</span></strong></p><ul><li><span>Abstract on pooled cardiac safety for Annamycin accepted for poster presentation at ASCO 2026 (May 30, Poster Board #8).</span></li><li><span>Independent cardiac review covered 90 patients from five completed trials; 78 had source-verified LVEF assessments.</span></li><li><span>Median cumulative Annamycin dose 660 mg/m2 (95% CI 645–690); most doses exceeded conventional anthracycline lifetime limits.</span></li><li><span>No significant change in LVEF from baseline to final (mean diff -0.12%; 95% CI -1.34 to 1.09; p=0.84) and no dose or age correlation with LVEF change.</span></li><li><span>Serial ECGs, biomarkers, cardiac AEs and global longitudinal strain showed no evidence of drug-induced cardiotoxicity, supporting MIRACLE trial rationale.</span></li></ul><p><span>Original SEC Filing: </span>Moleculin Biotech, Inc. [ MBRX ] - 8-K - May. 22, 2026</p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

MBRX

LABU

SBIO

<p>Moleculin announced the acceptance of a poster at ASCO 2026, presenting pooled cardiac safety data for Annamycin, indicating no drug-induced cardiotoxicity. The independent review involved 90 patients, with a median Annamycin dose of 660 mg/m2. No significant changes in LVEF were observed, and serial ECGs and biomarkers supported the findings, reinforcing the rationale for the MIRACLE trial.</p>

TradingView

Moleculin Biotech

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Moleculin poster acceptance at ASCO shows pooled Annamycin cardiac safety across 90 patients